Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2000 1
2001 4
2002 4
2003 5
2004 4
2005 5
2006 14
2007 11
2008 12
2009 13
2010 9
2011 13
2012 10
2013 13
2014 7
2015 11
2016 14
2017 18
2018 15
2019 11
2020 5
2021 9
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. Glaviano A, et al. Among authors: kulke mh. Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6. Mol Cancer. 2023. PMID: 37596643 Free PMC article. Review.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: kulke mh. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Yurgelun MB, et al. Among authors: kulke mh. J Clin Oncol. 2017 Apr 1;35(10):1086-1095. doi: 10.1200/JCO.2016.71.0012. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135145 Free PMC article.
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB 3rd. Kunz PL, et al. Among authors: kulke mh. J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19. J Clin Oncol. 2023. PMID: 36260828 Free PMC article. Clinical Trial.
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Yao JC, et al. Among authors: kulke mh. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. Lancet. 2016. PMID: 26703889 Free PMC article. Clinical Trial.
Carcinoid tumors.
Kulke MH, Mayer RJ. Kulke MH, et al. N Engl J Med. 1999 Mar 18;340(11):858-68. doi: 10.1056/NEJM199903183401107. N Engl J Med. 1999. PMID: 10080850 Review. No abstract available.
Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors.
Hoffman SE, Dowrey TW, Villacorta Martin C, Bi K, Titchen B, Johri S, DelloStritto L, Patel M, Mackichan C, Inga S, Chen J, Grimaldi G, Napolitano S, Wakiro I, Wu J, Yeung J, Rotem A, Sicinska E, Shannon E, Clancy T, Wang J, Denning S, Brais L, Besson NR, Pfaff KL, Huang Y, Kao KZ, Rodig S, Hornick JL, Vigneau S, Park J, Kulke MH, Chan J, Van Allen EM, Murphy GJ. Hoffman SE, et al. Among authors: kulke mh. Sci Adv. 2023 Sep 29;9(39):eadd9668. doi: 10.1126/sciadv.add9668. Epub 2023 Sep 27. Sci Adv. 2023. PMID: 37756410 Free PMC article.
Metastatic pancreatic cancer.
Kulke MH. Kulke MH. Curr Treat Options Oncol. 2002 Dec;3(6):449-57. doi: 10.1007/s11864-002-0065-5. Curr Treat Options Oncol. 2002. PMID: 12392635 Review.
Neuroendocrine tumors.
Kulke MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA; National Comprehensive Cancer Networks. Kulke MH, et al. J Natl Compr Canc Netw. 2012 Jun 1;10(6):724-64. doi: 10.6004/jnccn.2012.0075. J Natl Compr Canc Netw. 2012. PMID: 22679117
Somatostatin Analogues in Neuroendocrine Tumors.
Kulke MH. Kulke MH. J Natl Compr Canc Netw. 2016 Mar;14(3):241-2. doi: 10.6004/jnccn.2016.0029. J Natl Compr Canc Netw. 2016. PMID: 26957610 No abstract available.
200 results